Summary
Smith–Lemli–Opitz syndrome (SLOS) is an autosomal recessive metabolic disorder. SLOS is caused by the mutations in the gene for 3β-hydroxysterol Δ7 reductase (DHCR7; EC 1.3.1.21), which maps to chromosome 11q12-13. DHCR7 catalyses the final step in cholesterol biosynthesis—the reduction of 7-dehydrocholesterol to cholesterol. Clinical severity ranges from mild dysmorphism to severe congenital malformation and intrauterine lethality. Pregnant women are offered a biochemical screening test for Down syndrome in the second trimester, where the suspicion for SLOS could be registered, when the unconjugated estriol (uE3) level appears low. A group of 456 fetuses with a high risk for SLOS were examined by DNA analysis. We confirmed SLOS in 5 fetuses and 11 fetuses were carriers. One novel mutation (p.G30A) was detected. The most frequently found mutations, c.964-1> C and p.W151X, are also the most severe ones. At least one of these mutations was detected in each fetus with SLOS. This suggests that the biochemical screening of pregnant women probably uncovers mainly more severely affected fetuses. We confirmed SLOS also in two patients whose prenatal screening was negative. Both of them had nonsense mutation on one allele. It stands to reason that some modifying factors may play a role in the reduction of the uE3 level in the mother’s serum.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bradley LA, Canick JA, Palomaki GE, Haddow JE (1997) Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. Am J Obstet Gynecol 176(3): 531-35.
Bradley LA, Palomaki GE, Knight GJ, et al (1999) Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith–Lemli–Opitz (RSH) syndrome fetuses. Am J Med Genet 82(4): 355-58.
Bzduch V, Behulova D, Skoduva J (2000) Incidence of Smith–Lemli–Opitz syndrome in Slovakia. Am J Med Genet 90: 260.
Cooper MK, Wassif CA, Krakowiak PA, et al (2003) A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet 33(4): 508-13.
Correa-Cerro LS and Porter FD (2005) 3β-hydroxysterol Δ7-reductase and the Smith–Lemli–Opitz syndrome. Mol Genet Metab 84: 112-26.
Craig WY, Haddow JE, Palomaki GE, et al (2006) Identifying Smith–Lemli–Opitz syndrome in conjunction with prenatal screening for Down syndrome. Prenat Diagn 26(9): 842-49.
Fitzky BU, Witsch-Baumgartner M, Erdel M, et al (1998) Mutations in the Δ7-sterolreductase gene in the patients with the Smith–Lemli–Opitz syndrome. Proc Natl Acad Sci 95: 8181-186.
Fitzky BU, Glossmann H, Utermann G, Moebius FF (1999) Molecular genetics of the Smith–Lemli–Opitz syndrome and postsqualen sterol metabolism. Curr Opin Lipidol 10(2): 123-31.
Glass IA, Lam RC, Chang T, Roitman E, Shapiro LJ, Shackleton CH (1998) Steroid sulphatase deficiency is the major cause of extremely low oestriol production at mid-pregnancy: a urinary steroid assay for the discrimination of steroid sulphatase deficiency from other causes. Prenat Diagn 18(8): 789-00.
Irons M, Elias ER, Tint GS, Batta AK (1993) Defective cholesterol biosynthesis in Smith–Lemli–Opitz syndrome. Lancet 341: 1414.
Kelley RI (1997) A new face for an old syndrome. Am J Med Genet 68: 251-56.
Kelley RI (1998) RSH/Smith–Lemli–Opitz syndrome: mutations and metabolic morphogenesis. Am J Hum Genet 63: 322-26.
Kozák L, Kuhrová V, Blaková M, et al (1995) Phenylketonuria mutations and their relation to RFLP haplotypes at the PAH locus in Czech PKU families. Hum Genet 96: 472-76.
Kozák L, Francová H, Hrabincová E, et al (2000) Smith–Lemli–Opitz syndrome: molecular-genetic analyses of ten families. J Inherit Metab Dis 23: 409-12.
Krakowiak PA, Nwokoro NA, Wassif CA, et al (2000) Mutation analysis and description of sixteen RSH/Smith–Lemli–Opitz syndrome patients: polymerase chain reaction-based assays to simplify genotyping. Am J Med Genet 94(3): 214-27.
Kratz LE and Kelley RI (1999) Prenatal diagnosis of the RSH/Smith–Lemli–Opitz syndrome. Am J Med Genet 82(5): 376-81.
Loeffler J, Utermann G, Witsch-Baumgartner M (2002) Molecular prenatal diagnosis of Smith–Lemli–Opitz syndrome is reliable and efficient. Prenat Diagn 22: 827-30.
Moebius FF, Fitzky BU, Lee JN, Paik Y-K, Glossmann H (1998) Molecular cloning and expression of the human delta 7-sterol reductase. Proc Natl Acad Sci USA 95: 1899-902.
Nowaczyk MJ and Waye JS (2001) The Smith–Lemli–Opitz syndrome: a novel metabolic way of understanding developmental biology, embryogenesis, and dysmorphology. Clin Genet 59(6): 375-86.
Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM (1999) Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol 176(5): 1046-051.
Palomaki GE, Bradley LA, Knight GJ, Craig WY, Haddow JE (2002) Assigning risk for Smith–Lemli–Opitz syndrome as part of 2nd trimester screening for Down’s syndrome. J Med Screen 9(1): 43-4.
Porter FD (2000) RSH/Smith–Lemli–Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol Genet Metab 71(1–2): 163-74.
Porter JA, Young KE, Beachy PA (1996) Cholesterol modification of hedgehog signaling proteins in animal development. Science 274: 255-59.
Putnam AR, Szakacs JG, Opitz JM, Byrne JL (2005) Prenatal death in Smith–Lemli–Opitz/RSH syndrome. Am J Med Genet 138(1): 61-5.
Ryan AK, Bartlett K, Clayton P, et al (1998) Smith–Lemli–Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet 35: 558-65.
Smith DW, Lemli L, Opitz JM (1964) A newly recognized syndrome of multiple congenital anomalies. J Pediatr 64: 210-17.
Tint GS, Irons M, Elias ER, et al (1994) Defective cholesterol biosynthesis associated with the Smith–Lemli–Opitz syndrome. N Engl J Med 330: 107-13.
Tint GS, Salen G, Batta AK, et al (1995) Correlation of severity and outcome with plasma sterol levels in variants of the Smith–Lemli–Opitz syndrome. J Pediatr 127: 82-7.
Wassif CA, Maslen C, Kachilele-Linjewile S, et al (1998) Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith–Lemli–Opitz syndome. Am J Hum Genet 63: 55-2.
Waterham HR and Wanders RJA (2000) Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith–Lemli–Opitz syndrome. Biochim Biophys Acta 1529(1–2): 340-56.
Witsch-Baumgartner M, Fitzky BU, Ogorelkova M, et al (2000) Mutational spectrum in the Delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith–Lemli–Opitz syndrome. Am J Hum Genet 66(2): 402-12.
Witsch-Baumgartner M, Loffler J, Utermann G (2001a) Mutations in the human DHCR7 gene. Hum Mutat 17(3): 172-82.
Witsch-Baumgartner M, Ciara E, Loffler J, et al (2001b) Frequency gradients of DHCR7 mutations in patients with Smith–Lemli–Opitz syndrome in Europe: evidence for different origins of common mutations. Eur J Hum Genet 9(1): 45-0.
Yu H, Lee MH, Starck L, et al (2000) Spectrum of delta(7)-dehydrocholesterol reductase mutations in patients with the Smith–Lemli–Opitz (RSH) syndrome. Hum Mol Genet 9(9): 1385-391.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Georg Hoffmann
Competing interests: None declared
References to electronic databases: Smith–Lemli–Opitz syndrome: OMIM 270400. 3β-Hydroxysterol Δ7 reductase: EC 1.3.1.21.
Rights and permissions
About this article
Cite this article
Blahakova, I., Makaturova, E., Kotrbova, L. et al. Molecular screening of Smith–Lemli–Opitz syndrome in pregnant women from the Czech Republic. J Inherit Metab Dis 30, 964–969 (2007). https://doi.org/10.1007/s10545-007-0710-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-007-0710-z